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In this issue of the Journal, Hughes et al. (1) present findings from
the well-known EPIC (European Prospective Investigation into
Cancer and Nutrition) study that show an increased risk of hepa-
tocellular carcinoma, gallbladder, and biliary tract cancer among
those with low serum concentrations of selenium and selenoprotein
P (SePP). The authors suggest that the next step ought to be the
initiation of randomized field trials in Western Europe of dietary
selenium supplementation to reduce the risk of hepatobiliary cancer.
The EPIC study has many strengths, and the results of this new
analysis need to be reckoned with. Nonetheless, it is disappoint-
ing to see such an august group of investigators present an epi-
demiologic analysis that incorporates methods that have long
been considered inappropriate or suboptimal, such as comparing
mean levels of exposure between cases and controls or evaluating
statistical interaction (by using product terms in a multiplicative
model) instead of biological interaction. Another problem is the
lamentable emphasis on whether the associations reported were
significant, rather than focusing on their magnitude (2–4). Be-
cause they categorized results according to what was significant
and what was not, their findings appear to be less internally con-
sistent than they actually are.
Despite these drawbacks, it is clear that Hughes et al. found
a moderately strong, inverse association between these cancer sites
and both selenium and SePP. Are these associations causal? These
findings are the latest in an array of results on selenium and cancer,
from trials and nonexperimental epidemiologic studies, that indicate
associations both large and small, positive and negative (5). The
most recently reported trials indicate no effect or even an excess
risk (6). The divergence of results seems to be more than just the
play of chance, and calls for an explanation (7). One possibility is
uncontrolled confounding. It seems likely that the complicated
multicollinearity among dietary nutrients and other variables, such
as toxic chemicals, cannot be fully controlled with multivariable
models (8, 9). Furthermore, it appears that the confounding prob-
lem is more difficult to disentangle for cancer than for cardiovas-
cular disease or diabetes (10). Inadequate control for lifestyle
factors, such as smoking, may also be a relevant issue in sele-
nium research, as recently suggested by an elegant study by Beane
Freeman et al. (11), which showed that confounding from smok-
ing intensity or duration could explain the inverse association
between selenium status and bladder cancer found in some
observational studies. The reported association was not seen in
a randomized trial (5, 6).
It is worth noting the discrepancy between results from the
study by Hughes et al. and the evidence from “low bias” intervention
studies, such as those reviewed in Vincenti et al. (5), and specifically
that of the Eastern Cooperative Oncology Group (ECOG) 5597,
carried out in patients with resected stage I non–small-cell lung
cancer (12). In that study, 6 new cases of liver, gallbladder, or bile
duct neoplasms were found among 1040 selenium-treated subjects
compared with none among the 521 placebo-control individuals.
Another limitation of the study by Hughes et al.—one that is
shared by most nonexperimental studies on dietary selenium—is
the lack of information about selenium speciation. There is growing
awareness of the vastly different nutritional and toxicologic effects
of the various chemical species of this metalloid (6), mirroring
what is currently known about the role of selenoproteins in both
preventing and promoting cancer (13).
Given this background, no matter how much weight we assign
the present findings, when they are coupled with the existing lit-
erature it is a stretch to infer a straightforward causal connection
as an explanation for the observed associations. Nevertheless, let
us suppose that selenium and SePP do have a causal role in the
occurrence of hepatobiliary cancers. Would it then be reasonable
to undertake randomized field trials of selenium supplements as
a next step, as suggested by Hughes et al.? The cost of a properly
conducted randomized field trial is enormous, even for high-
incidence endpoints such as prostate cancer, as exemplified by
the SELECT (Selenium and Vitamin E Cancer Prevention Trial)
study (14), which cost ;$114 million. That study involved
.35,000 participants in selenium, vitamin E, and placebo arms,
whereas a study planned to discern a 25% decrease in risk of
hepatobiliary cancer with conventional power would require on
the order of 180,000 participants followed for 10 y, and thus
would be so costly as to be infeasible. Furthermore, intervention
studies (5, 6) and a natural experiment (15) have pointed to a large
array of possible toxic effects of even low-dose chronic over-
exposure to selenium. These effects include high-grade prostate
*To whom correspondence should be addressed. E-mail: marco.vinceti@
unimore.it.
First published online July 13, 2016; doi: 10.3945/ajcn.116.139469.









alavasi user on 15 February 2021
cancer, type 2 diabetes, and amyotrophic lateral sclerosis (6). The
possibility of these adverse effects raises worrisome ethical ques-
tions about long-term administration of selenium to humans.
Thus, despite the renewed interest in selenium raised by this
provocative report, the results should be considered critically and
skeptically before raising expectations of a meaningful benefit
from selenium supplements. We need to remind ourselves of
the divergent literature, the complex relation between selenium
species and human diseases (16), and the disappointment that
resulted when intervention studies deflated the hope raised by
earlier epidemiologic studies that selenium would reduce the
risk of several other cancers (6, 7).
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